Clear market notes built around the JSE, the rand, and what matters locally.

2026-07-17 18:30 • The Motley Fool Positive Axe Cap view: Selective

Novo Nordisk's oral Wegovy launch has regained market share in the GLP-1 weight-loss drug market, capturing ~89% of oral weight-loss medication prescriptions in the U.S. However, Eli Lilly's Foundayo has potential advantages including fewer food restrictions and upcoming label expansions for multiple indications. Both companies remain well-positioned in the fast-growing anti-obesity market with strong pipelines.

Axe note: Novo Nordisk’s oral Wegovy dominates the weight-loss pill market, yet Eli Lilly’s pipeline and label expansions keep it firmly in the race.

2026-07-17 18:29 • The Motley Fool Negative Axe Cap view: Bearish

Pinterest co-founder and director Benjamin Silbermann sold 93,750 shares worth $2.1 million on July 14-15, 2026, reducing his indirect equity stake by 87% through a pre-planned Rule 10b5-1 trading arrangement. Despite maintaining over 1.2 million derivative securities, the large sale size and Pinterest's 35% stock decline over the past year amid advertising headwinds have raised investor concerns about confidence in the company.

Axe note: Pinterest co-founder dumps significant stock amid ad revenue pressures.

2026-07-17 18:27 • The Motley Fool Neutral Axe Cap view: Neutral

WD-40 earns a Superscore of 79 out of 100 for its strong operational efficiency, robust margins (56.6%), and disciplined focus on high-margin maintenance products. However, the stock trades at a stretched valuation (P/E of 37.7) with limited growth prospects, structural headwinds from commoditization and the EV transition, and is expected to underperform the S&P 500 over the next five years.

Axe note: WD-40’s operational strengths don’t justify its high valuation or future growth potential.